Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New wrinkle filler faces off against market leader

NCT ID NCT07265791

Symptom relief Sponsor: Jetema Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study compares a new injectable filler, JTM104, to the well-known Juvederm for temporarily softening moderate to deep smile lines (nasolabial folds). About 100 adults will receive both treatments in a blinded fashion to see if JTM104 works just as well and is safe. The goal is to offer another option for people looking to reduce facial wrinkles.

Why investors are watching

Jetema is testing JTM104, an injectable filler, against Juvederm Ultra Plus XC in a 100-person study for moderate to severe nasolabial folds. For a small company, this pivotal trial could determine whether JTM104 can compete with an established product in the aesthetic market. The result matters because it may shape the company's commercial future and regulatory path.

If it works: If JTM104 proves non-inferior to Juvederm, Jetema could gain a credible product to market in a competitive field. That outcome might open revenue opportunities and attract partnerships.

If it fails: If the trial fails or shows JTM104 is less safe or effective, Jetema may face delays or lose the chance to commercialize this product. Trials often fail, so a negative result is a real possibility.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 19 to 75 years * Voluntarily provided written informed consent * Moderate to severe symmetrical nasolabial folds (score 3 or 4 on a 5-point severity scale on both sides) * Agree to discontinue other facial dermatologic treatments (e.g., fillers, botulinum toxin, laser) during the study * Able to understand instructions and comply with study procedures Exclusion Criteria: * Untreated scars or facial skin infections/diseases affecting the mid/lower face within the past year * History of severe allergy or hypersensitivity to device components * Facial invasive procedures within the past 6 months (including surgery, laser, botulinum toxin) * Use of certain medications (anticoagulants, immunosuppressants, steroids) within specified washout periods * Participation in other interventional clinical trials within 4 weeks before screening or during study * Non-compliance with contraception requirements or pregnancy/lactation during study * Deemed unsuitable by investigator for any other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasolabial folds, wrinkles are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasolabial folds, wrinkles

Contacts and locations

Locations

  • Dankook University Hospital

    Cheonan, Chungcheongnam-do, South Korea

  • Inje University Sanggye Paik Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.